Expert Review of Anti-infective Therapy最新文献_第7页

Evaluation of health-related quality of life in patients receiving outpatient parenteral antimicrobial therapy (OPAT) in a UK setting. 对英国接受门诊肠外抗菌疗法（OPAT）患者的健康相关生活质量进行评估。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-11-01 Epub Date: 2024-03-25 DOI: 10.1080/14787210.2024.2334059

Oyewole Christopher Durojaiye, Evangelos I Kritsotakis

{"title":"Evaluation of health-related quality of life in patients receiving outpatient parenteral antimicrobial therapy (OPAT) in a UK setting.","authors":"Oyewole Christopher Durojaiye, Evangelos I Kritsotakis","doi":"10.1080/14787210.2024.2334059","DOIUrl":"10.1080/14787210.2024.2334059","url":null,"abstract":"Background: Studies assessing the benefits of outpatient parenteral antimicrobial therapy (OPAT) have paid less attention to patient-centered factors such as patients' experiences and their health-related quality of life (HRQoL).Research design and methods: Prospective before-and-after quasi-experimental study enrolled adult patients receiving OPAT at a tertiary hospital in Derbyshire, UK, between October 2022 and October 2023. Consenting patients completed paired EQ-5D-3 L questionnaires before OPAT initiation and upon completion of therapy or 30 days after its commencement (whichever occurred first). Changes and predictors of change in HRQoL indicators and associations with clinical outcomes (treatment failure, adverse events, and 30-day unplanned readmission) were examined.Results: Health state index and visual analogue scale (EQ VAS) scores of 162 enrolled patients at baseline were significantly lower than the UK population averages, but the patients experienced significant improvements in both scores and in four EQ-5D dimensions (mobility, self-care, usual activities, and pain/discomfort). Baseline health index and EQ VAS scores were significant independent predictors of positive changes in HRQoL scores.Conclusions: OPAT is associated with improved patient-reported quality of life and facilitates early return to work or school. Nevertheless, it is crucial to closely monitor patients with a lower baseline quality of life to optimize their overall OPAT experience.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"987-995"},"PeriodicalIF":4.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140174161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The emergence of Japanese encephalitis as a public health concern in New South Wales Australia. 日本脑炎成为澳大利亚新南威尔士州的公共卫生问题。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-10-01 Epub Date: 2024-07-23 DOI: 10.1080/14787210.2024.2381824

Prakasini Satapathy, Sarvesh Rustagi, Israa Habeeb Naser, Shilpa Gaidhane, Quazi Syed Zahiruddin, Rachana Mehta, Vasso Apostolopoulos, Ranjit Sah

引用次数: 0

Management of resistant and refractory cytomegalovirus infections after transplantation. 移植后耐药和难治性巨细胞病毒感染的管理。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-10-01 Epub Date: 2024-09-05 DOI: 10.1080/14787210.2024.2399647

Justin H Pham, Raymund R Razonable

{"title":"Management of resistant and refractory cytomegalovirus infections after transplantation.","authors":"Justin H Pham, Raymund R Razonable","doi":"10.1080/14787210.2024.2399647","DOIUrl":"10.1080/14787210.2024.2399647","url":null,"abstract":"Introduction: Cytomegalovirus (CMV) is a classic opportunistic infection in transplant recipients. Treatment-refractory CMV infections are of concern, with growing identification of strains that have developed genetic mutations which confer resistance to standard antiviral therapy. Resistant and refractory CMV infections are associated with worse patient outcomes, prolonged hospitalization, and increased healthcare costs.Areas covered: This article provides a comprehensive practical overview of resistant and refractory CMV infections in transplant recipients. We review the updated definitions for these infections, antiviral pharmacology, mechanisms of drug resistance, diagnostic workup, management strategies, and host-related factors including immune optimization.Expert opinion: Resistant and refractory CMV infections are a significant contributor to post-transplant morbidity and mortality. This is likely the result of a combination of prolonged antiviral exposure and active viral replication in the setting of intensive pharmacologic immunosuppression. Successful control of resistant and refractory infections in transplant recipients requires a combination of immunomodulatory optimization and appropriate antiviral drug choice with sufficient treatment duration.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"855-866"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical effectiveness of nirmatrelvir plus ritonavir for patients with COVID-19 and preexisting psychiatric disorders. 尼马瑞韦加利托那韦对 COVID-19 和原有精神障碍患者的临床疗效。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-10-01 Epub Date: 2024-05-11 DOI: 10.1080/14787210.2024.2351555

Ting-Hui Liu, Jheng-Yan Wu, Po-Yu Huang, Wan-Hsuan Hsu, Min-Hsiang Chuang, Ya-Wen Tsai, Chih-Cheng Lai, Charles Lung-Cheng Huang

{"title":"Clinical effectiveness of nirmatrelvir plus ritonavir for patients with COVID-19 and preexisting psychiatric disorders.","authors":"Ting-Hui Liu, Jheng-Yan Wu, Po-Yu Huang, Wan-Hsuan Hsu, Min-Hsiang Chuang, Ya-Wen Tsai, Chih-Cheng Lai, Charles Lung-Cheng Huang","doi":"10.1080/14787210.2024.2351555","DOIUrl":"10.1080/14787210.2024.2351555","url":null,"abstract":"Objectives: This study assessed the clinical effectiveness of the combination of nirmatrelvir and ritonavir (NMV-r) in treating nonhospitalized patients with COVID-19 who have preexisting psychiatric disorders.Methods: Patients diagnosed with COVID-19 and psychiatric disorders between 1 March 2020, and 1 December 2022, were included using the TriNetX network. The primary outcome was the composite outcome of all-cause emergency department (ED) visits, hospitalization, or death within 30 days.Results: Propensity score matching yielded two cohorts of 20,633 patients each. The composite outcome of all-cause ED visits, hospitalization, or death within 30 days was 3.57% (737 patients) in the NMV-r cohort and 5.69% (1176) in the control cohort, resulting in a reduced risk in the NMV-r cohort (HR: 0.657; 95% confidence interval (CI): 0.599-0.720). The NMV-r cohort exhibited a lower risk of all-cause hospitalization (HR: 0.385; 95% CI: 0.328-0.451) and all-cause death (HR: 0.110; 95% CI: 0.053-0.228) compared with the control group.Conclusion: NMV-r could mitigate the risk of adverse outcomes in nonhospitalized patients with COVID-19 and preexisting psychiatric disorders. However, only a limited number of patients in this population received adequate treatment, thus emphasizing the importance of promoting its appropriate use.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"885-893"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140860401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence and prescription of antibiotic therapy: present and future. 人工智能与抗生素治疗处方：现在与未来。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-10-01 Epub Date: 2024-08-18 DOI: 10.1080/14787210.2024.2386669

Daniele Roberto Giacobbe, Cristina Marelli, Sabrina Guastavino, Alessio Signori, Sara Mora, Nicola Rosso, Cristina Campi, Michele Piana, Ylenia Murgia, Mauro Giacomini, Matteo Bassetti

{"title":"Artificial intelligence and prescription of antibiotic therapy: present and future.","authors":"Daniele Roberto Giacobbe, Cristina Marelli, Sabrina Guastavino, Alessio Signori, Sara Mora, Nicola Rosso, Cristina Campi, Michele Piana, Ylenia Murgia, Mauro Giacomini, Matteo Bassetti","doi":"10.1080/14787210.2024.2386669","DOIUrl":"10.1080/14787210.2024.2386669","url":null,"abstract":"Introduction: In the past few years, the use of artificial intelligence in healthcare has grown exponentially. Prescription of antibiotics is not exempt from its rapid diffusion, and various machine learning (ML) techniques, from logistic regression to deep neural networks and large language models, have been explored in the literature to support decisions regarding antibiotic prescription.Areas covered: In this narrative review, we discuss promises and challenges of the application of ML-based clinical decision support systems (ML-CDSSs) for antibiotic prescription. A search was conducted in PubMed up to April 2024.Expert opinion: Prescribing antibiotics is a complex process involving various dynamic phases. In each of these phases, the support of ML-CDSSs has shown the potential, and also the actual ability in some studies, to favorably impacting relevant clinical outcomes. Nonetheless, before widely exploiting this massive potential, there are still crucial challenges ahead that are being intensively investigated, pertaining to the transparency of training data, the definition of the sufficient degree of prediction explanations when predictions are obtained through black box models, and the legal and ethical framework for decision responsibility whenever an antibiotic prescription is supported by ML-CDSSs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"819-833"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug Inspector as an antibiotic steward: challenges and recommendations to implement national action plan of Pakistan on antimicrobial resistance. 作为抗生素管理员的药品检查员：实施巴基斯坦抗菌药耐药性国家行动计划的挑战和建议。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-10-01 Epub Date: 2024-06-19 DOI: 10.1080/14787210.2024.2368825

Mishal Bajwa, Shairyar Afzal, Sadaf Areej Sheikh, Zikria Saleem

{"title":"Drug Inspector as an antibiotic steward: challenges and recommendations to implement national action plan of Pakistan on antimicrobial resistance.","authors":"Mishal Bajwa, Shairyar Afzal, Sadaf Areej Sheikh, Zikria Saleem","doi":"10.1080/14787210.2024.2368825","DOIUrl":"10.1080/14787210.2024.2368825","url":null,"abstract":"Background: Despite significant measures, low- and middle-income countries (LMICs), including Pakistan, struggle to curtail non-prescription antibiotic sales, enforce regulations, and implement National Action Plan (NAP) against antimicrobial resistance (AMR). NAP Pakistan entails drug inspectors (DIs) to ensure prescription-based sales of antibiotics. This study seeks to understand the perspective of DIs regarding antimicrobial sales without prescription, underlying factors, and policy implementation status.Methods: A qualitative study employing a semi-structured interview guide using in-depth interviews with purposively selected 17 DIs was conducted. Interviews were transcribed verbatim, and data were analyzed following a thematic analysis framework utilizing MAXQDA 2022 software.Results: Five main themes emerged after data analysis: (1) drug inspector - the regulator of the antimicrobial armamentarium, (2) the policy context, (3) awareness regarding AMR, (4) barriers to combatting AMR, and (5) the way forward: strategies and recommendations.Conclusion: A weak regulatory framework, low level of awareness, quackery, vested interests, and socio-economic factors augment inappropriate antibiotic utilization. Opting for better policies and strengthening the DI fraternity as outlined in NAP Pakistan is recommended. Recognizing drug inspectors as effective surveilling units and mobilizing field force against irrational antibiotic utilization is the need of the hour and requires policy reformation.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"907-920"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice. 多卢替拉韦+拉米夫定和比替拉韦/恩曲他滨/替诺福韦-阿拉芬酰胺在HIV感染的早期抗逆转录病毒治疗中的比较：临床实践的初步结果。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-10-01 Epub Date: 2023-11-07 DOI: 10.1080/14787210.2023.2279719

Lin Gan, Xiaoxin Xie, Yanhua Fu, Xiaoyan Yang, Shujing Ma, Linghong Kong, Chunli Song, Yebing Song, Tingting Ren, Hai Long

{"title":"Comparison of dolutegravir+Lamivudine and bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral therapy-naïve patients infected with HIV: preliminary results from clinical practice.","authors":"Lin Gan, Xiaoxin Xie, Yanhua Fu, Xiaoyan Yang, Shujing Ma, Linghong Kong, Chunli Song, Yebing Song, Tingting Ren, Hai Long","doi":"10.1080/14787210.2023.2279719","DOIUrl":"10.1080/14787210.2023.2279719","url":null,"abstract":"Background: The efficacy and safety of dolutegravir+lamivudine (DTG +3TC) and bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) have been demonstrated in clinical trials of treatment-naïve therapy. However, real-life data are lacking. We investigated and compared the virological outcomes and safety of DTG + 3TC with BIC/FTC/TAF in an adult cohort of people living with HIV (PLWH).Research design and methods: We performed a retrospective cohort analysis of PLWH who were naïve to antiretroviral therapy and initiated the antiretroviral regimen of DTG + 3TC or BIC/FTC/TAF from January 2020 to March 2022. Treatment effectiveness, defined as the capability of treatment to achieve viral suppression (viral load < 50 copies/mL), was analyzed. Changes in immunology, metabolism, liver and renal function after 48 weeks of treatment were evaluated.Results: At 48 weeks, both groups showed high viral suppression, with 82.4% (108/131) and 89% (129/145) of the patients in the BIC/FTC/TAF and DTG + 3TC groups, respectively, having viral suppression (OR = 0.58, 95% CI: 0.29-1.15, P = 0.3). No differences existed in immunology, metabolism, liver and renal function; however, BIC/FTC/TAF led to greater weight gain.Conclusions: Both optimization strategies showed high tolerability in antiretroviral therapy-naïve patients, with no differences in virological efficacy; however, BIC/FTC/TAF may be related to the risk of weight gain risk. Further research is required to evaluate this problem.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"877-884"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71479877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging and alternative strategies for the treatment of nontuberculous mycobacterial infections. 治疗非结核分枝杆菌感染的新策略和替代策略。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-10-01 Epub Date: 2024-08-21 DOI: 10.1080/14787210.2024.2395003

Amritavarshini Sreekumar, Anil Kumar, Raja Biswas, Lalitha Biswas

{"title":"Emerging and alternative strategies for the treatment of nontuberculous mycobacterial infections.","authors":"Amritavarshini Sreekumar, Anil Kumar, Raja Biswas, Lalitha Biswas","doi":"10.1080/14787210.2024.2395003","DOIUrl":"10.1080/14787210.2024.2395003","url":null,"abstract":"Introduction: Nontuberculous mycobacteria (NTM) infections have emerged as a significant clinical challenge due to their intrinsic multidrug resistance and the limited efficacy of existing treatments. These infections are becoming increasingly prevalent, with a need for new and effective therapeutic strategies.Areas covered: This review addresses several key aspects of NTM infections: i) pathogenesis and epidemiology; ii) the limitations and challenges of current treatment options; iii) emerging and alternative therapeutic strategies; iv) advanced drug delivery systems such as nanoparticles and efflux pump inhibitors; v) innovative antibacterial alternatives like antimicrobial peptides, bacteriophage therapy, and phytochemicals; and vi) other potential treatment modalities such as inhaled nitric oxide, small molecules, surgical debridement, phototherapy, and immunomodulatory therapy.Expert opinion: Personalized medicine, advanced drug delivery systems, and alternative therapies hold promise for the future of NTM treatment. Early and accurate identification of NTM species, enabled by improved diagnostic methods, is critical for tailoring treatment regimens. Emerging therapies show promise against drug-resistant NTM strains, but overcoming barriers like clinical trials, regulatory hurdles, and high production costs is crucial. Continued research and innovation are essential to improve treatment efficacy and patient outcomes.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"835-853"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of the COVID-19 pandemic on the utilisation and quality of antibiotic use in the Scottish primary care setting: a population-based segmented interrupted time-series analysis. COVID-19 大流行对苏格兰基层医疗机构抗生素使用情况和质量的影响：基于人群的分段间断时间序列分析。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-10-01 Epub Date: 2024-06-14 DOI: 10.1080/14787210.2024.2363485

Hayam Al Balushi, Amanj Kurdi, Najla Almutairi, Kirmanj Ismail Baker, Karwan M Amen, Hardee Karwi, Andrew Seaton, Brian Godman

{"title":"Impact of the COVID-19 pandemic on the utilisation and quality of antibiotic use in the Scottish primary care setting: a population-based segmented interrupted time-series analysis.","authors":"Hayam Al Balushi, Amanj Kurdi, Najla Almutairi, Kirmanj Ismail Baker, Karwan M Amen, Hardee Karwi, Andrew Seaton, Brian Godman","doi":"10.1080/14787210.2024.2363485","DOIUrl":"10.1080/14787210.2024.2363485","url":null,"abstract":"Background: Inappropriate use of antibiotics is expected to increase during the COVID-19 pandemic, but there are limited data on COVID-19's long-term impact. We assessed the impact of COVID-19 on the quantity and quality of antibiotic use in Scotland.Research design and methods: A segmented interrupted time series was applied to monthly dispensed antibiotics using prescription cost analysis data from March/2019 to March/2023. Antibiotic use was quantified using the number of items dispensed/1000 inhabitants (TIDs) and defined daily dose/1000 inhabitants/day (DIDs). The quality of antibiotic use was assessed using key quality indicators including the WHO AWaRe classification, proportion of broad-spectrum and \"4C\"-antibiotics.Results: Overall, for all antibiotics, there was a non-significant increase in TIDs and DIDs before the first lockdown (March/2020) (β1), but a decline in the level immediately after the first (β2) and second lockdowns (β4) (November/2020), albeit non-significant. However, a significant increase in the time trend after the second lockdown (β5) for all antibiotic classes was observed. COVID-19 had no negative impact on AWaRe utilisation, with the proportion of all antibiotics from the Access group increasing from 76% in March/2019 to 90% in March/2023. The proportion of \"4C\" antibiotic reduced significantly after the second lockdown.Conclusions: Neither the utilisation nor the quality of total antibiotic use appeared to have been significantly affected by COVID-19.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"895-905"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141247683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel agents in development for the treatment of resistant Gram-negative infections. 正在开发用于治疗耐药性革兰氏阴性菌感染的新型制剂。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-18 DOI: 10.1080/14787210.2024.2407068

Matteo Bassetti,Barbara Larosa,Antonio Vena,Daniele Roberto Giacobbe

{"title":"Novel agents in development for the treatment of resistant Gram-negative infections.","authors":"Matteo Bassetti,Barbara Larosa,Antonio Vena,Daniele Roberto Giacobbe","doi":"10.1080/14787210.2024.2407068","DOIUrl":"https://doi.org/10.1080/14787210.2024.2407068","url":null,"abstract":"INTRODUCTIONSeveral novel agents are in advanced stages of clinical development, potentially expanding our treatment options against third- and fourth-generation cephalosporin-resistant and carbapenem-resistant Gram-negative bacteria (GNB), including those pathogens for which the current number of effective treatments is limited.AREAS COVEREDThis review focuses on agents that have completed or ongoing phase-3 studies. A PubMed search was conducted up to 31 May 2024.EXPERT OPINIONNovel agents in late-stage clinical development belong to the β-lactam or β-lactam/β-lactamase inhibitor combinations class and display variable antimicrobial activity depending on the specific β-lactamases expressed by GNB, particularly carbapenemases. While many of these novel agents demonstrate in vitro activity against carbapenem-resistant GNB, their efficacy has mainly been evaluated in phase-3 randomized controlled trials (RCT) for infections caused by carbapenem-susceptible GNB. Although evidence from real-world observational studies is generally less robust than that from RCT, it could be crucial for updating clinical guidelines on treating carbapenem-resistant GNB with these new agents in the absence of dedicated RCT.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":"45 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142262093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0